David Veitch, Basilea CEO
Basilea tosses an oncology drug back to Merck, doubling down on antibiotics in revamp
Swiss biotech Basilea Pharmaceutica has shed one of its last pipeline ties with oncology as it makes a move to concentrate on antibiotics in a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
